Bavarian Nordic A/S released its earnings results on Nov 14, 2025. The company reported $0.729 earnings per share for the quarter, beating the consensus estimate of N/A by $0.729.

Is Bavarian Nordic A/S overvalued?

According to Wall Street analysts Bavarian Nordic A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bavarian Nordic A/S pay dividends?

Bavarian Nordic A/S pays a Notavailable dividend of $0.426 which represents an annual dividend yield of N/A. See more information on Bavarian Nordic A/S dividends here

What is Bavarian Nordic A/S’s EPS estimate?

Bavarian Nordic A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bavarian Nordic A/S have?

Bavarian Nordic A/S has 237,712,550 shares outstanding.

What happened to Bavarian Nordic A/S’s price movement after its last earnings report?

Bavarian Nordic A/S reported an EPS of $0.729 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.936%.

Which hedge fund is a major shareholder of Bavarian Nordic A/S?

Currently, no hedge funds are holding shares in BVNRY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bavarian Nordic Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

20.01%

Trailing 12-Months

Asset Growth

14.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Bavarian Nordic (BVNRY) Earnings & Revenues

Historic Earnings Reports

BVNRY Company Deck

BVNRY Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong growth in both revenue and market expansion for Bavarian Nordic, especially in the Travel Health and Public Preparedness segments. However, there were some challenges related to the refinement of financial guidance and delays affecting the U.S. launch of the chikungunya vaccine.View all BVNRY earnings summaries